Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome
Abstract The global burden of Guillain-Barré syndrome (GBS), an immune-mediated neuropathy, remains poorly characterized during the COVID-19 pandemic. We analyzed age-standardized years lived with disability (YLD) for GBS from 1990 to 2021 using GBD 2021 data and COVID-19 vaccination coverage from O...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01239-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333823732449280 |
|---|---|
| author | Xīn Gào Chen Zhao Junting Yang Ziming Yang Jingnan Feng Siyan Zhan Dongsheng Fan Zhike Liu |
| author_facet | Xīn Gào Chen Zhao Junting Yang Ziming Yang Jingnan Feng Siyan Zhan Dongsheng Fan Zhike Liu |
| author_sort | Xīn Gào |
| collection | DOAJ |
| description | Abstract The global burden of Guillain-Barré syndrome (GBS), an immune-mediated neuropathy, remains poorly characterized during the COVID-19 pandemic. We analyzed age-standardized years lived with disability (YLD) for GBS from 1990 to 2021 using GBD 2021 data and COVID-19 vaccination coverage from Our World in Data, focusing on 2020–2021. During the pandemic, GBS YLD rates rose dramatically, with greater increases seen in low-SDI regions, females and individuals aged 15–29 years. Higher vaccination coverage was inversely associated with GBS disability burden, exhibiting a non-linear protective effect at moderate to high coverage levels. Causal mediation analysis indicated that 44.6% of this association was mediated by reductions in COVID-19 incidence, highlighting both direct and indirect neuroprotective benefits of vaccination programs. These results underscore the importance of sustaining and expanding the vaccine rollout to mitigate the secondary neurological burden associated with emerging infections. |
| format | Article |
| id | doaj-art-ffe208b0a6374be2b78fbfdffde636d4 |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-ffe208b0a6374be2b78fbfdffde636d42025-08-20T03:45:44ZengNature Portfolionpj Vaccines2059-01052025-08-0110111010.1038/s41541-025-01239-1Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndromeXīn Gào0Chen Zhao1Junting Yang2Ziming Yang3Jingnan Feng4Siyan Zhan5Dongsheng Fan6Zhike Liu7Department of Epidemiology and Biostatistics, School of Public Health, Peking UniversityDepartment of Neurology, Peking University Third HospitalDepartment of Epidemiology and Biostatistics, School of Public Health, Peking UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Peking UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Peking UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Peking UniversityDepartment of Neurology, Peking University Third HospitalDepartment of Epidemiology and Biostatistics, School of Public Health, Peking UniversityAbstract The global burden of Guillain-Barré syndrome (GBS), an immune-mediated neuropathy, remains poorly characterized during the COVID-19 pandemic. We analyzed age-standardized years lived with disability (YLD) for GBS from 1990 to 2021 using GBD 2021 data and COVID-19 vaccination coverage from Our World in Data, focusing on 2020–2021. During the pandemic, GBS YLD rates rose dramatically, with greater increases seen in low-SDI regions, females and individuals aged 15–29 years. Higher vaccination coverage was inversely associated with GBS disability burden, exhibiting a non-linear protective effect at moderate to high coverage levels. Causal mediation analysis indicated that 44.6% of this association was mediated by reductions in COVID-19 incidence, highlighting both direct and indirect neuroprotective benefits of vaccination programs. These results underscore the importance of sustaining and expanding the vaccine rollout to mitigate the secondary neurological burden associated with emerging infections.https://doi.org/10.1038/s41541-025-01239-1 |
| spellingShingle | Xīn Gào Chen Zhao Junting Yang Ziming Yang Jingnan Feng Siyan Zhan Dongsheng Fan Zhike Liu Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome npj Vaccines |
| title | Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome |
| title_full | Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome |
| title_fullStr | Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome |
| title_full_unstemmed | Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome |
| title_short | Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome |
| title_sort | impact of covid 19 vaccination coverage on global disability burden of guillain barre syndrome |
| url | https://doi.org/10.1038/s41541-025-01239-1 |
| work_keys_str_mv | AT xingao impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT chenzhao impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT juntingyang impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT zimingyang impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT jingnanfeng impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT siyanzhan impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT dongshengfan impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome AT zhikeliu impactofcovid19vaccinationcoverageonglobaldisabilityburdenofguillainbarresyndrome |